An Open-label Study of ALTO-300 in Adults With Major Depressive Disorder
Latest Information Update: 02 May 2024
At a glance
- Drugs Agomelatine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alto Neuroscience
- 07 Dec 2023 According to an Alto Neuroscience media release, data from the trial presented at the 62nd annual meeting of the American College of Neuropsychopharmacology (ACNP)
- 07 Dec 2023 Results published in the Alto Neuroscience Media Release
- 19 May 2023 Status changed from active, no longer recruiting to completed.